Regular treatment with formoterol for chronic asthma: serious adverse events [PDF]
, 2012 Epidemiological evidence has suggested a link between beta(2)-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are safe ...
Altman +17 more
core +1 more source
Frontiers in Pharmacology, 2018 Background: Prospective pharmacological studies on breathomics profiles in COPD patients have not been previously reported. We assessed the effects of treatment and withdrawal of an extrafine inhaled corticosteroid (ICS)-long-acting β2-agonist (LABA ...
Paolo Montuschi +14 more
doaj +1 more source
Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma [PDF]
, 2010 Background Formoterol is a long-acting beta(2)-agonist but because it has a fast onset of action it can also be used as a relief medication. Objectives To asses the efficacy and safety of formoterol as reliever therapy in comparison to short-acting ...
Cates, CJ, Welsh, EJ
core +1 more source
Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events [PDF]
, 2012 An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews.ObjectivesWe set out to compare the risks of mortality and non-fatal serious adverse events in ...
Altman +18 more
core +1 more source
Inhaled corticosteroids versus long-acting beta -agonists for chronic obstructive pulmonary disease (Review). [PDF]
, 2011 Long-acting beta(2)-agonists and inhaled corticosteroids can be used as maintenance therapy by patients with moderate to severe chronic obstructive pulmonary disease. These interventions are often taken together in a combination inhaler.
Agarwal +105 more
core +2 more sources
Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events (Review) [PDF]
, 2009 Background Epidemiological evidence has suggested a link between beta2-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are ...
Cates, CJ, Jaeschke, R, Lasserson, TJ
core +1 more source
Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma
BMC Pulmonary Medicine, 2019 Background and objective The dose-response relationship of inhaled corticosteroid (ICS)/fast-onset long acting beta agonist (LABA) reliever therapy has not been formally addressed.
Richard Beasley +7 more
doaj +1 more source
Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN) [PDF]
, 2016 Evidence that enables us to identify, assess, and access the small airways in asthma and chronic obstructive pulmonary disease (COPD) has led INTERASMA (Global Asthma Association) and WAO to take a position on the role of the small airways in these ...
A. Cruz +51 more
core +14 more sources
Respiratory Research, 2012 Background Increased pulmonary arterial vascular smooth muscle (PAVSM) cell proliferation is a key pathophysiological component of pulmonary vascular remodeling in pulmonary arterial hypertension (PH).
Goncharova Elena A +3 more
doaj +1 more source
Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children [PDF]
, 2008 BackgroundCombination therapies are frequently recommended as maintenance therapy for people with asthma, whose disease is not adequately controlled with inhaled steroids.
Aalbers +64 more
core +1 more source